Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages 241-247

  Ellis, Giovanina M ^a   Huang, Sharon ^b   Hitti, Jane ^c   Frenkel, Lisa M ^a,c  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antiretroviral discontinuation; antiretroviral drug resistance; HIV 1; Lamivudine; minority genotypes; nelfinavir; Nevirapine; oligonucleotide ligation assay (OLA); pregnancy; Zidovudine

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; OLIGONUCLEOTIDE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE LIGATION ASSAY; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NELFINAVIR; NEVIRAPINE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SELECTION, GENETIC;

EID: 80054950128     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822b4edc     Document Type: Article

References (33)

1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494. (Pubitemid 34456340)
2. Recommendations for Use of Antiretroviral Drugs in Pregnant HIVInfected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 2010. Available at: http://aidsinfo.nih.gov/ContentFiles/ PerinatalGL.pdf. Accessed May 18, 2010.
3. El-SadrWM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. (Pubitemid 44837777)
4. Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008;22:2279-2289.
5. Paredes R, Cheng I, Kuritzkes DR, et al. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS. 2010;24:45-53.
6. Pilotto JH. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. In: XVII International AIDS Conference. Mexico City, Mexico; August 3-8, 2008.
7. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-776. (Pubitemid 38859341)
8. Stanford HIV Drug Resistance Database. Stanford, CA: Stanford University; 2003. Available at: http://hivdb.stanford.edu/. Accessed May 14, 2010.
9. Ellis GM, Page LC, Burman BE, et al. Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNAwith a sensitive assay. J Acquir Immune Defic Syndr. 2009;51:283-289.
10. Ellis GM, Mahalanabis M, Beck IA, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drugresistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol. 2004;42: 3670-3674. (Pubitemid 39045698)
11. Manual for Genotyping Kits for the Detection of HIV-1 pol Drug-Resistance Mutations by an Oligonucleotide Ligation Assay. 2007. Available at: http://depts.washington.edu/idimmweb/facultyMember.php?sort=8. Accessed December 10, 2010.
12. Soto-Ramirez LE, Rodriguez-Diaz R, Duran AS, et al. Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Res Hum Retroviruses. 2008;24:797-804. (Pubitemid 351871671)
13. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63-67. (Pubitemid 40111019)
14. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77-F82. (Pubitemid 30336080)
15. Yuen GJ, Morris DM, Mydlow PK, et al. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995;35:1174-1180. (Pubitemid 26020039)
16. Laine C, Newschaffer CJ, Zhang D, et al. Adherence to antiretroviral therapy by pregnantwomen infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167-173. (Pubitemid 30045634)
17. Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003; 17:1195-1199. (Pubitemid 36667762)
18. Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis. 2004;39:736-740. (Pubitemid 39180449)
19. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther. 2004;76:588-597. (Pubitemid 39601548)
20. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62:309-315. (Pubitemid 44215531)
21. Read JS, Best BM, Stek AM, et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008; 9:875-882.
22. Bryson YJ, Mirochnick M, Stek A, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008;9:115-125. (Pubitemid 351804395)
23. Perno CF, Yarchoan R, Cooney DA, et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med. 1988;168: 1111-1125.
24. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344: 472-480. (Pubitemid 32164898)
25. Wagner TA, Kress CM, Beck I, et al. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol. 2010;48:1555-1561.
26. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510-5518. (Pubitemid 351705258)
27. WHO. Rapid Advice: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva: WHO; 2009.
28. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
29. Palmer S, Boltz V, Maldarelli F, et al. Addition of short-course Combivir to single-dose nevirapine reduces the selection of NPV-resistant HIV-1 with infrequent emergence of 3TC-resistant variants. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3-6, 2008.
30. Lallemant M, Ngo-Giang-Huong N, Jourdain G, et al. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis. 2010; 50:898-908.
31. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-147. (Pubitemid 46089674)
32. Jourdain G,Wagner TA, Ngo-Giang-Huong N, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis. 2010;50:1397-1404.
33. Lockman S, HughesMD,McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363:1499-1509.